Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Blossomhill Therapeutics

BLSM

----

OverviewOverview NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Blossomhill Therapeutics (BLSM)

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. It...

Open: --
High: --
Low: --
Prev. Close: --
Volume: --
Turnover: --
Avg Price: --
Bid/Ask Ratio: --
Amplitude: --
52wk High: --
Volume Ratio: --
Turnover Ratio: --

52wk Low: --
Float Mkt Cap: --
Market Cap: --
P/E^TTM: --
P/E^Dynamic: --
P/E^Static: --
EPS^TTM: --
EPS^Dynamic: --
EPS^Static: --
BVPS: --
P/B: --
Circulating Supply: --
Dividend Yield^TTM: --
Dividend^TTM: --
Shares: --
Min lot size: --
Currency: --

Blossomhill Therapeutics Analyst Rating

Forecast & Rating

Sep 15, 2026

Price forecast

$32.2020.06%

Forecast & RatingStrong buy

5analysts

Strong buy80.00%
Buy20.00%
Hold0.00%
Sell0.00%
Strong sell0.00%

Strong buy: 4
Buy: 1
Hold: 0
Sell: 0
Strong sell: 0

News

rttnews · 16 hours ago
Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG
businessinsider · 1 day ago, 08:45 PM
BlossomHill closes up 18% on strongest day since August IPO
Tip Ranks · 2 days ago, 05:35 PM
BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained
TradingView · 2 days ago, 11:33 AM
BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned